Contacts

MedinCell announces a capital increase of a c.€30 million

February 10, 2021

MedinCell (FR0004065605 – MEDCL), a clinical stage pharmaceutical company developing a portfolio of longacting injectable products in various therapeutic areas (the “Company”), announces today a capital increase of €c.30 million through an offering to qualified investors, both French and international, by way of an accelerated bookbuilding process (the “Offering”).
Bryan, Garnier & Co Limited1 and ODDO BHF SCA are acting as Joint Global Coordinators and Joint Bookrunners.

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.